ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1023

The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)

Chaim Putterman1, Armando Gabrielli2, Alexandra Balbir-Gurman3, Pennina Safer4, Keren Jakobi-Brook4, Rachel Sorek4, Ilana Gluzman4, Steve Wallace5 and Irun R. Cohen4,6, 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, 2Istituto di Clinica Medica dell'Università di Ancona, Ancona, Italy, Ancona, Italy, 3Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel, Haifa, Israel, 4ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, 5ImmunArray Inc., VA, USA, Richmond, VA, 6Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, autoimmune diseases, Diagnosis and rheumatic disease, Diagnostic Tests

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to provide extensive autoantibody profiling in human serum. We previously described the SLE-Key Rule-Out test, which distinguishes SLE patients from HC with 94% sensitivity, 75% specificity, and a negative predictive value (NPV) of 93%1,2,3. Here, we report the use of the autoimmune discovery iCHIP to distinguish between HC and subjects with SLE, RA, SSc, SS, and the APS.

Methods:

We examined IgM and IgG autoantibodies binding to 519 antigens (1038 features) in the sera of HC subjects (N=136), and in patients with SLE (N=30), RA (N=30), SSc (N=40), SS (N=20), and APS (N=16).  FDR-adjusted p-values were calculated for each univariate test. Three independent multivariate classification methods were applied: Support Vector Machine (SVM), Quadratic Discriminant Analysis (QDA) and Naive Bayesian classifier (NB). Classifier training and testing were performed based on 10-fold cross validation on all samples, and the performance of each classifier was determined.

Results:

Univariate analysis revealed multiple statistically significant separating reactivities. We found that IgG autoantibody reactivity to the connective tissue antigen receptor leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) differentiated HC subjects with all of the 5 diseases with a p value of 2.8E-63. Other highly significant autoantigen reactivities included connective tissue proteins such as collagen III (p = 6.5E-26 (IgM)) and collagen II (p = 5E-22 (IgG)). Figure 1 shows anti-LAIR-1 data comparing HC subjects to each of the 5 diseases; each of the three classification methods differentiated between HC and subjects with autoimmune diseases. The typical mean classifier performance was 93% sensitivity, 96% specificity, and 95% accuracy.  Interestingly, LAIR-1 appears to function as a “checkpoint” down-regulator of immune reactivity4 ; thus, it is possible that anti- LAIR-1 represent a target for therapeutic discovery and also may be pathogenic, and predispose to a variety of autoimmune conditions.

Conclusion:

Autoantibody specificities detected by the autoimmune discovery iCHIP successfully distinguished between HC individuals and individuals with several autoimmune rheumatic diseases, including SLE, RA, SSc, SS, and APS. These preliminary results are based on relatively small numbers of serum samples, but are very promising and warrant additional validation in larger cohorts of autoimmune and HC subjects.

 

References: 1Putterman et al; J Immunol Methods 2016 2Cohen IR, LOA 2016 3Massenburg et al; LOA 2017 4Tang et al; J Immunol 2012

Acknowledgements: Authors wish to acknowledge Cohen-Gindi O, Lerner M, Tarnapolski O, Blumenstein Y, Javaherian A, Pitts J, Barton M and Wong E


Disclosure: C. Putterman, Consultant, 5; A. Gabrielli, None; A. Balbir-Gurman, None; P. Safer, None; K. Jakobi-Brook, None; R. Sorek, None; I. Gluzman, None; S. Wallace, None; I. R. Cohen, Consultant, 5.

To cite this abstract in AMA style:

Putterman C, Gabrielli A, Balbir-Gurman A, Safer P, Jakobi-Brook K, Sorek R, Gluzman I, Wallace S, Cohen IR. The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-autoimmune-discovery-ichip-distinguishes-healthy-individuals-hc-from-those-with-sle-rheumatoid-arthritis-ra-scleroderma-ssc-sjogrens-syndrome-ss-and-the-anti-phospholipid-synd/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-autoimmune-discovery-ichip-distinguishes-healthy-individuals-hc-from-those-with-sle-rheumatoid-arthritis-ra-scleroderma-ssc-sjogrens-syndrome-ss-and-the-anti-phospholipid-synd/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology